[vc_row css_animation=”fadeIn” full_width=”stretch_row_content_no_spaces” content_placement=”middle” css=”.vc_custom_1713374750961{padding-top: 120px !important;padding-bottom: 120px !important;background-image: url(http://backups.levoengage.com/wp-content/uploads/2024/04/Kyzatrex-Campaign-Grill-1-scaled.webp?id=3826) !important;background-position: 0 0 !important;background-repeat: no-repeat !important;}” wpex_bg_position=”center center” el_class=”HCP-LP-HERO mobile-hero-section main-container” visibility=”hidden-phone” min_height=”800px”][vc_column][vc_row_inner remove_bottom_col_margin=”true” css=”.vc_custom_1712085190114{padding-right: 0px !important;padding-left: 0px !important;}” el_class=”hcp_about_banner_row”][vc_column_inner width=”1/2″]

Testosterone Deficiency
is a Chronic Disease™

[vc_column_text css_animation=”fadeInLeft” responsive_text=”true” css=”” color=”#ffffff” font_size=”16″ font_weight=”400″]Low T affects an estimated[/vc_column_text]

20 million men

[vc_column_text css_animation=”fadeInLeft” responsive_text=”true” css=”” color=”#ffffff” font_size=”18″ font_weight=”400″]from ages 20-65 in the U.S.1,2[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=”” text_align=”right” color=”#ffffff”]Actor Portrayal[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row css_animation=”fadeIn” full_width=”stretch_row_content_no_spaces” content_placement=”middle” css=”.vc_custom_1712759501728{padding-top: 120px !important;padding-bottom: 120px !important;background-image: url(http://backups.levoengage.com/wp-content/uploads/2024/03/Kyzatrex-Campaign-Grill-1.svg?id=1216) !important;background-position: 0 0 !important;background-repeat: no-repeat !important;}” wpex_bg_position=”center center” el_class=”HCP-LP-HERO mobile-hero-section main-container” visibility=”visible-phone” el_id=”mobile-swap”][vc_column][vc_row_inner remove_bottom_col_margin=”true” css=”.vc_custom_1712085190114{padding-right: 0px !important;padding-left: 0px !important;}” el_class=”hcp_about_banner_row”][vc_column_inner width=”1/2″][vc_column_text css=”.vc_custom_1722537404151{padding-bottom: 15px !important;}” text_align=”right” color=”#ffffff”]Actor Portrayal[/vc_column_text]

Testosterone Deficiency
is a Chronic Disease™

[vc_column_text css_animation=”fadeInLeft” responsive_text=”true” css=”” color=”#ffffff” font_size=”16″ font_weight=”400″]Low T affects an estimated[/vc_column_text]

20 million men

[vc_column_text css_animation=”fadeInLeft” responsive_text=”true” css=”” color=”#ffffff” font_size=”18″ font_weight=”400″]from ages 20-65 in the U.S.1,2[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/2″][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row full_width=”stretch_row” tablet_fullwidth_cols=”yes” css=”.vc_custom_1712759256680{padding-top: 80px !important;padding-bottom: 80px !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”Help-address-sec” wpex_bg_position=”top”][vc_column][vc_row_inner el_class=”help_address_row”][vc_column_inner][vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″]Elevate Testosterone Replacement Therapy (TRT) in Your Practice[/vc_column_text]

Help Address the Men’s Health Crisis

[vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ font_weight=”400″]American men are experiencing a decline in testosterone levels, and healthcare providers like you can help address the issue.
In a 24-year study, researchers noted a substantial age-independent decline in testosterone levels among males in the U.S. Since the study’s inception in 1987, researchers found that men born in more recent years have lower testosterone levels than previous generations, with average levels declining by about 1% per year.3[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner gap=”30″ remove_bottom_col_margin=”true” css=”.vc_custom_1712815750131{margin-top: 100px !important;}” el_class=”what_does_this_mean_row”][vc_column_inner el_class=”pb-20 remove_col_bottom_margin_mobile” width=”1/2″]

What Does This Mean?

[vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ font_weight=”400″]This decline in testosterone is a public health issue, one that speaks directly to the core of men’s health and well-being. Healthcare providers like you are on the frontlines of this crisis. Your knowledge and influence can truly make a difference.[/vc_column_text][/vc_column_inner][vc_column_inner el_class=”pb-20 remove_col_bottom_margin_mobile” width=”1/2″]

What Can You Do About It?

[vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ font_weight=”400″]Talk to your patients about the prevalence of hypogonadism and metabolic health. Encourage testing for total testosterone, free testosterone, and sex hormone binding globulin (SHBG), and be part of the solution with testosterone replacement therapy.[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1712607406181{padding-top: 60px !important;padding-bottom: 20px !important;background-color: #eef5f9 !important;}” el_class=”third-sec-row mobile-plr-15″][vc_column][vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ text_align=”center”]Help Your Patients Be the Hero of Their Lives Again[/vc_column_text]

Prevalence of Low Testosterone

[vc_row_inner gap=”30″][vc_column_inner el_class=”remove_col_bottom_margin_mobile” width=”1/2″ css=”.vc_custom_1712086990404{padding-top: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;background-color: #dcebf7 !important;}”][vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ text_align=”left”]Only 5-10% of men with low testosterone are being treated with testosterone therapy.4[/vc_column_text][/vc_column_inner][vc_column_inner el_class=”remove_col_bottom_margin_mobile” width=”1/2″ css=”.vc_custom_1712086995890{padding-top: 20px !important;padding-bottom: 20px !important;padding-left: 20px !important;background-color: #dcebf7 !important;}”][vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ text_align=”left”]Low T can affect men at any age, including approximately 35% of men older than 45.5[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1712607315793{padding-top: 60px !important;padding-bottom: 50px !important;}” el_class=”forth-sec-row mobile-plr-15″][vc_column][vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ text_align=”center”]Concerned About the Safety of TRT?[/vc_column_text]

The Safety of Testosterone Replacement Therapy

[vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ font_weight=”400″ text_align=”center” width=”1000px” align=”center”]Insights from the TRAVERSE Study

The TRAVERSE study is the largest randomized clinical trial of testosterone replacement therapy (TRT) to date. It was designed to examine the effects of TRT (topical 1.62% testosterone gel) versus placebo on cardiovascular and prostate health, a long-debated topic within the medical community. The study enrolled 5,246 men aged 45 to 80 with documented hypogonadism and pre-existing or a high risk of cardiovascular disease.[/vc_column_text][vc_row_inner gap=”30″ css=”.vc_custom_1712815801878{margin-top: 60px !important;}” el_class=”small_container_1170″][vc_column_inner el_class=”remove_col_bottom_margin_mobile” width=”1/2″ css=”.vc_custom_1763502474879{padding-right: 0px !important;padding-left: 0px !important;}”]

Cardiovascular Health and TRT6

[vc_column_text css_animation=”none” css=”” font_weight=”400″ el_class=”primary-dark body-md”]Study Participants

  • Patients with preexisting cardiovascular disease: 2,847
  • Patients with at elevated cardiovascular risk: 2,357
  • Baseline median serum testosterone level: 227 ng per deciliter; interquartile range, 188 to 258
[/vc_column_text][vc_column_text css_animation=”none” css=”.vc_custom_1763501716632{padding-top: 50px !important;}” font_weight=”400″ el_class=”primary-dark body-md mobile-pb-40″]Findings from the TRAVERSE Study

  • At 12 months, the median increase from baseline in serum testosterone levels was 148 ng per deciliter; interquartile range,
34 to 312 (compared with a median increase of 14 ng per deciliter; interquartile range, −21 to 56 in the placebo group).
  • TRT did not increase the risk of major heart problems compared to the placebo group.
  • There were no clinically meaningful differences in the incidence of secondary cardiovascular end-point events.
[/vc_column_text][/vc_column_inner][vc_column_inner el_class=”remove_col_bottom_margin_mobile” width=”1/2″ css=”.vc_custom_1763502505390{padding-right: 0px !important;padding-left: 0px !important;}”]

Prostate Health and TRT7

[vc_column_text css_animation=”none” css=”” font_weight=”400″ el_class=”primary-dark body-md”]Study Participants

  • Men at greater risk of prostate cancer (having prostate-specific antigen (PSA) concentrations greater than 3.0 ng/mL and International Prostate Symptom Score (IPSS) greater than 19) were excluded, leaving a total of 5,204 participants.
[/vc_column_text][vc_column_text css_animation=”none” css=”.vc_custom_1763501757191{padding-top: 50px !important;}” font_weight=”400″ el_class=”primary-dark body-md”]Findings from the TRAVERSE Study

  • There were no significant differences between testosterone-treated and placebo groups.
  • Incidences of high-grade or any prostate cancer were low.
  • Incidences of acute urinary retention, invasive surgical procedures, or prostate biopsy between testosterone-treated and placebo groups did not differ significantly.
  • Testosterone treatment was associated with a greater increase in PSA levels than placebo at 12 months, but there was no significant between-group difference in PSA levels after month 12.
[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row full_width=”stretch_row_content” remove_bottom_col_margin=”true” css=”.vc_custom_1712607324158{background-color: #eef5f9 !important;}” el_class=”py-40″][vc_column el_class=”main-container”][vc_row_inner el_class=”small_container_1170″][vc_column_inner el_class=”remove_col_bottom_margin_mobile”][vc_column_text css_animation=”none” responsive_text=”true” css=”” color=”#20325c” font_size=”20″ text_align=”center”]These findings from the TRAVERSE study help provide a clearer picture of TRT’s safety. However, you should still monitor patients’ blood pressure during treatment with KYZATREX and check for prostate cancer or any other prostate problems before starting and during treatment with KYZATREX.[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row css=”.vc_custom_1763501941968{margin-top: 60px !important;padding-right: 15px !important;padding-left: 15px !important;}” el_class=”mobile-p-l-r-15 last-row”][vc_column][vc_column_text css_animation=”none” css=”” el_class=”body-sm primary-dark difficult_text”]References:

  1. Li Y, Liu M, Cui Y, et al. Increased risk of testosterone deficiency is associated with the systemic immune-inflammation index: a population-based cohort study. Front Endocrinol. 2022; 13:975773. doi: 10.3389/fendo.2022.974773
  2. National Population by Characteristics: 2020-2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022- SYAEXN). U.S. Census Bureau. https://www.census.gov/data/tables/ time-series/demo/popest/2020s-national-detail.html. Accessed September 11, 2023.
  3. Travison TG, Araujo AB, O’Donnell AB, et al. A Population-Level Decline in Serum Testosterone Levels in American Men. J Clin Endocrinol Metab. January 2007, 92(1):196-202.
  4. Krakowsky Y, Grober E. Testosterone deficiency – Establishing a Biochemical Diagnosis. EJIFCC. 2015 Mar; 26(2): 105–113.PMID: 27683486; PMCID: PMC4975356.
  5. Endocrine Society.”Hypogonadism in Men | Endocrine Society.” Endocrine.org, Endocrine Society, 31 January 2024, https://www.endocrine.org/patient-engagement/endocrine-library/hypogonadism. Accessed 2 Feb. 2024.
  6. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023; 389:107-117. DOI: 10.1056/NEJMoa2215025
  7. Bhasin S, Travison TG, Pencina KM, et al. Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial. JAMA Netw Open. 2023;6(12):e2348692. doi:10.1001/jamanetworkopen.2023.48692
[/vc_column_text][/vc_column][/vc_row]

Important Safety Information for KYZATREX (testosterone undecanoate)

KYZATREX® (testosterone undecanoate) capsules, CIII, is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

More Info
X

Leaving the Consumer Site

You are now entering a site that is for US healthcare professionals only. Products or treatments described on this site are available in the United States but may not be available in all other countries. If you are interested in becoming a KYZATREX prescriber, please enter your information below.

You can also continue to the Prescriber site now to learn more about KYZATREX and becoming a prescriber.